Cargando…
Metastatic Latency, a Veiled Threat
Metastatic relapse is observed in cancer patients with no clinical evidence of disease for months to decades after initial diagnosis and treatment. Disseminated cancer cells that are capable of entering reversible cell cycle arrest are believed to be responsible for these late metastatic relapses. D...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691038/ https://www.ncbi.nlm.nih.gov/pubmed/31447846 http://dx.doi.org/10.3389/fimmu.2019.01836 |
_version_ | 1783443283167412224 |
---|---|
author | Kim, Kangsan Marquez-Palencia, Mauricio Malladi, Srinivas |
author_facet | Kim, Kangsan Marquez-Palencia, Mauricio Malladi, Srinivas |
author_sort | Kim, Kangsan |
collection | PubMed |
description | Metastatic relapse is observed in cancer patients with no clinical evidence of disease for months to decades after initial diagnosis and treatment. Disseminated cancer cells that are capable of entering reversible cell cycle arrest are believed to be responsible for these late metastatic relapses. Dynamic interactions between the latent disseminated tumor cells and their surrounding microenvironment aid cancer cell survival and facilitate escape from immune surveillance. Here, we highlight findings from preclinical models that provide a conceptual framework to define and target the latent metastatic phase of tumor progression. The hope is by identifying patients harboring latent metastatic cells and providing therapeutic options to eliminate metastatic seeds prior to their emergence will result in long lasting cures. |
format | Online Article Text |
id | pubmed-6691038 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66910382019-08-23 Metastatic Latency, a Veiled Threat Kim, Kangsan Marquez-Palencia, Mauricio Malladi, Srinivas Front Immunol Immunology Metastatic relapse is observed in cancer patients with no clinical evidence of disease for months to decades after initial diagnosis and treatment. Disseminated cancer cells that are capable of entering reversible cell cycle arrest are believed to be responsible for these late metastatic relapses. Dynamic interactions between the latent disseminated tumor cells and their surrounding microenvironment aid cancer cell survival and facilitate escape from immune surveillance. Here, we highlight findings from preclinical models that provide a conceptual framework to define and target the latent metastatic phase of tumor progression. The hope is by identifying patients harboring latent metastatic cells and providing therapeutic options to eliminate metastatic seeds prior to their emergence will result in long lasting cures. Frontiers Media S.A. 2019-08-06 /pmc/articles/PMC6691038/ /pubmed/31447846 http://dx.doi.org/10.3389/fimmu.2019.01836 Text en Copyright © 2019 Kim, Marquez-Palencia and Malladi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Kim, Kangsan Marquez-Palencia, Mauricio Malladi, Srinivas Metastatic Latency, a Veiled Threat |
title | Metastatic Latency, a Veiled Threat |
title_full | Metastatic Latency, a Veiled Threat |
title_fullStr | Metastatic Latency, a Veiled Threat |
title_full_unstemmed | Metastatic Latency, a Veiled Threat |
title_short | Metastatic Latency, a Veiled Threat |
title_sort | metastatic latency, a veiled threat |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691038/ https://www.ncbi.nlm.nih.gov/pubmed/31447846 http://dx.doi.org/10.3389/fimmu.2019.01836 |
work_keys_str_mv | AT kimkangsan metastaticlatencyaveiledthreat AT marquezpalenciamauricio metastaticlatencyaveiledthreat AT malladisrinivas metastaticlatencyaveiledthreat |